Pharvaris Aims for Key Data Readout as FDA Review Nears
Event summary
- Pharvaris expects topline data from CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in Q3 2026.
- FDA review of deucrictibant IR NDA underway with PDUFA date set for April 23, 2027; EMA validated MAA in July 2026.
- Company raised €132.3 million in May 2026, extending cash runway into 2028.
- Peng Lu promoted to President, consolidating research, development, and commercial functions under one leadership structure.
The big picture
Pharvaris is advancing deucrictibant through pivotal trials as it prepares for potential regulatory approvals in HAE. The company's strategic focus on oral bradykinin B2 receptor antagonists positions it to address unmet needs in bradykinin-mediated angioedema, competing with injectable therapies. With a strong cash position and leadership realignment, Pharvaris aims to establish a new standard of care in this niche but growing market.
What we're watching
- Regulatory Milestones
- Whether the CHAPTER-3 data readout in Q3 2026 will support deucrictibant XR's regulatory pathway and commercial positioning.
- Market Readiness
- How Pharvaris' pre-commercial activities will position it for a timely U.S. launch of deucrictibant IR, pending FDA approval in April 2027.
- Financial Discipline
- The pace at which Pharvaris will allocate its extended cash runway into 2028 to balance lifecycle management opportunities and capital discipline.
Related topics